FASTER

Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)

Arms / Cohorts

Experimental:Arm A (Elranatamab + Daratumumab)

Accepting patients

Active Comparator:Arm B (ASCT + lenalidomide/daratumumab)

Accepting patients

Experimental:Arm A1 (Late Intensification)

Accepting patients

Experimental:Arm B1 (Late Intensification)

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.